HAM/TSP introduction: systematic review of HAM/TSP clinical trials by Rebecca Anderson & Fabiola Martin
ORAL PRESENTATION Open Access
HAM/TSP introduction: systematic review of
HAM/TSP clinical trials
Rebecca Anderson1, Fabiola Martin1,2*
From 16th International Conference on Human Retroviruses: HTLV and Related Viruses
Montreal, Canada. 26-30 June 2013
Background
HTLV-1 Associated Myelopathy/Tropical Spastic Parapar-
esis (HAM/TSP) is a chronic disabling disease caused by
the retrovirus HTLV-1. It is a horrible, chronic, progres-
sing disease causing weakness of lower limbs, bladder,
bowel and erectile dysfunction, as well as pain in the lower
back and legs. HAM/TSP is associated with significantly
higher mortality and morbidity than the general popula-
tion. Currently there is no cure or antiviral treatment for
HTLV-1 and no internationally agreed treatment for
patients with HAM/TSP. We had two aims: to identify the
level of evidence of current medicinal treatment strategies
available to patients and clinicians and to identify drugs
that should be pursued for future clinical trials.
Methods
Using the PICOS search strategy and inclusion (adults+
HAM/TSP+drug treatment+ english), exclusion (sample
size <5, duration <2 weeks, <1985, in vitro, case studies) cri-
teria all papers identified in PubMed were analysed. Each
paper was scored individually using a modified quality
assessment questionnaire (scores 0-23).
Results
24/3012 manuscripts were included in the final analysis.
The most commonly tested drugs were corticosteroids
(9%) and interferon (29%) but only two were randomised
controlled trials (RCT) scoring 20. One was a double blind
placebo RCT (DBRCT) of zidovudine and lamivudine. The
other interferon DBRCT dose finding trial. None of the
trials were comparable due to very different outcome mea-
sures and patient groups. Therefore the level of evidence
was 4 to 5 only.
Conclusions
Most HAM/TSP treatment studies are either observa-
tional or proof- of-concept studies where outcomes can-
not be generalised. Both corticosteroids and interferon
need to be tested further in clinical trials with 90% pow-
ered sample sizes, either against placebo, or best local
standard of care or head to head against each other.
Authors’ details
1Department of Biology, University of York, York, UK. 2Centre for
Immunology and Infection, Department of Biology, Hull and York Medical
School, University of York, York, UK.
Published: 7 January 2014
doi:10.1186/1742-4690-11-S1-O26
Cite this article as: Anderson and Martin: HAM/TSP introduction:
systematic review of HAM/TSP clinical trials. Retrovirology 2014
11(Suppl 1):O26.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1Department of Biology, University of York, York, UK
Full list of author information is available at the end of the article
Anderson and Martin Retrovirology 2014, 11(Suppl 1):O26
http://www.retrovirology.com/content/11/S1/O26
© 2014 Martin; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
